BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 20.11.2020

Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the Biologics Price Competition and Innovation Act of 2009; Draft Guidance for Industry; Availability

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act." The question and answer (Q&A) format is intended to inform prospective applicants and facilitate the development of proposed biosimilars and proposed interchangeable biosimilars, as well as to describe FDA's interpretation of certain statutory requirements added by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). This draft guidance document provides new Q&As. It does not replace the draft guidance document entitled "New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2)," issued December 12, 2018.

Source: Federal Register — Food and Drug AdministrationOpen original release →